ATN-161 is a novel peptide antagonist of integrin α5β1. ATN-161 selectively binds to and blocks the receptor for integrin α5β1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. It has potential antineoplastic activity.
CAT# | R0965 |
CAS | 262438-43-7 |
Synonyms/Alias | ATN161; ATN 161; ATN-161; AcPHSCNNH2 |
M.F/Formula | C23H35N9O8S |
M.W/Mr. | 597.65 |
Sequence | Ac-PHSCN-NH2 |
Labeling Target | Integrin α5β1 |
Appearance | white solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Activity | Antagonist |
Areas of Interest | Cancer |
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
Studies on the binding affinities of darifenacin hydrobromide and human muscarinic receptor subtypes show strong ...
Fertirelin acetate, classified into peptide hormone, is a gonadotropin-releasing hormone (GnRH) antagonist or ...
Perindopril erbumine is an angiotensioncon vertingenzyme (ACE) inhibitor without sulfhydryl group. It is a chi ...
Development of Trofinetide Trofinetide was found in 2002 by Brimble's team at the University of Auckland i ...
R18 peptide is a non-phosphorylated ligand of 14-3-3 that was originally isolated from a phage display screen, ...